Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $20.8333.

ENTA has been the topic of a number of research analyst reports. Westpark Capital boosted their target price on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, September 30th. HC Wainwright initiated coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a "buy" rating and a $20.00 price target on the stock. JMP Securities raised their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a report on Wednesday. Finally, Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a "hold" rating to a "buy" rating and boosted their target price for the company from $14.00 to $20.00 in a research report on Wednesday, October 1st.

Enanta Pharmaceuticals Trading Up 1.4%

NASDAQ:ENTA opened at $11.46 on Friday. The stock has a market capitalization of $245.01 million, a price-to-earnings ratio of -2.65 and a beta of 0.89. The firm has a fifty day simple moving average of $8.64 and a two-hundred day simple moving average of $7.12. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The firm had revenue of $18.31 million during the quarter, compared to analysts' expectations of $16.21 million. Equities analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ENTA. US Bancorp DE bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth about $36,000. GAMMA Investing LLC bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth about $40,000. Farther Finance Advisors LLC grew its holdings in Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 5,779 shares in the last quarter. MetLife Investment Management LLC bought a new position in Enanta Pharmaceuticals during the 1st quarter worth about $72,000. Finally, Corton Capital Inc. purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at about $77,000. Institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.